Loading...
Targeted therapies for myeloproliferative neoplasms
The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment...
Na minha lista:
| Udgivet i: | Biomark Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6636147/ https://ncbi.nlm.nih.gov/pubmed/31346467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-019-0166-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|